TY  - JOUR
TI  - Second Primary Malignant Tumours in Patients with Renal Cell Carcinoma
AB  - Objective: The primary aim of our study is to establish the frequency and clinicopathological features of seconder primary malignant tumours (SPMTs) in cases with renal cell carcinoma (RCC). Materials and Methods: Pathology reports of 1129 RCC cases were checked retrospectively, and 70 RCC cases with SPMTs were included in the study. One patient had two and the other had three different SPMTs, so the total number of SPMTs was 73. According to occurrence times of SPMTs, the cases were classified as the antecedent, synchronous, subsequent and unknown. The first three groups were compared according to their clinicopathological features. Results: The incidence of SPMTs with RCC in our study was 6.2% and lower than that reported by many other studies. The most common SPMTs were gastrointestinal, breast, prostate, lung, thyroid carcinomas and haematolymphoid malignancies. Sixty-two per cent of SPMTs were developed as synchronous and subsequent. There was no statistically significant difference among groups regarding age, histological subtype and RCC size. Male patients had a higher percentage in the synchronous group. In all groups, the most common RCC subtype was clear cell carcinoma. The RCC subtype in cases with multiple SPMTs was papillary. The prostatic adenocarcinoma rate was remarkable in males with papillary type RCC. Conclusion: RCC can coexist with secondary malignancies. Therefore, when a new tumour appears in a patient with RCC in clinical follow-up, it is appropriate to evaluate that tumour histopathologically or cytopathologically regarding SPMT before accepting it as a metastatic spread.
AU  - Durak, Haydar
AU  - Uygun, Nesrin
AU  - ORUÇ, ERTUĞRUL
AU  - Yulek, Ozden
AU  - Gülle, Buğra Taygun
AU  - demir, hale
AU  - Gurses, Iclal
AU  - Demir, Deniz Nur
DO  - 10.4274/uob.galenos.2020.1785
PY  - 2021
JO  - Üroonkoloji Bülteni
VL  - 20
IS  - 1
SN  - 2147-2122
SP  - 49
EP  - 55
DB  - TRDizin
UR  - http://search/yayin/detay/505066
ER  -